ANGEN Fair Value & Analysis

Healthcare · TR · Market cap 2.1B TRY

Below-average quality, and screening another 44% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (6.74 TRY). The favourable scenario is already priced in.
• Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (3.73 TRY to 6.74 TRY) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 4, 2026.

How to read this chart

57‑month range 8.41 TRY – 23.13 TRY · fair‑value band 3.73 TRY – 6.74 TRY · the 9.30 TRY price screens above the 5.23 TRY fair value. Dashed = 300-day average. As of Aug 4, 2026.

Which stocks are undervalued right now? Check free Discover now →

Analysis

ANGEN (ANGEN) currently trades at 9.30 TRY, while our model-based Fair Value estimate is 5.23 TRY, implying the stock looks roughly 43.8% overvalued today. We read business quality at 26/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, ANGEN generated revenue of 788M TRY at a net margin of -35.8%. Revenue grew 19.1% year over year. It earns a return on equity of -16.4%. Net debt stands at 175M TRY. Fundamentals as of Aug 4, 2026

Our scenario range runs from 3.73 TRY (bear case) to 6.74 TRY (bull case); at 9.30 TRY, the current price sits above that range. The share trades about 42% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -44%, ANGEN screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (5.29 TRY) versus Multiples (5.23 TRY). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, rapid antigen test kits, and automated nucleic acid (NA) extraction instruments in Turkey.

Full company description

Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, rapid antigen test kits, and automated nucleic acid (NA) extraction instruments in Turkey. It offers microbiology, genetic disorder, multiplex panel, drug resistance sequencing, food testing kits, as well as sample collection and transport; and full automation, manual magnetic bead NA extraction, and automated NA extraction instrument kits. The company also provides products for diseases, such as hepatitis, herpes simplex virus, human papillomavirus, COVID-19, respiratory infections, monkeypox, human immunodeficiency virus, west nile virus, meningitis, brucella, crimean-congo hemorrhagic fever, sexually transmitted diseases, epstein-barr virus, tuberculosis, JC and BK polyomaviruses, cytomegalovirus, parvovirus B19, toxoplasmosis, ureaplasma, torque teno virus, factor V leiden mutation, factor II prothrombin mutation, methylenetetrahydrofolate reductase, influenza, and respiratory syncytial virus diseases. In addition, it is involved in installation of robots, developing software; and designing of devices for research of real-time PCR. Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. was founded in 2010 and is headquartered in Istanbul, Turkey.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

ANGEN reported revenue of 740M TRY in FY2025 versus 410M TRY in FY2021, a compound +15.9%/yr. Reported net income was −313M TRY in FY2025.

ANGEN screens 44% overvalued. Compare with Abbott Laboratories, →

Peer Group

Medical Devices · 401 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 4, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.